Cowen and Company set a $70.00 price target on Zoetis Inc. (NYSE:ZTS) in a research note released on Thursday morning. The firm currently has a buy rating on the stock.

ZTS has been the topic of a number of other reports. Deutsche Bank AG restated a buy rating and issued a $65.00 price objective (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. BMO Capital Markets restated a buy rating and issued a $60.00 price objective on shares of Zoetis in a research note on Thursday, May 4th. Zacks Investment Research upgraded Zoetis from a hold rating to a buy rating and set a $67.00 price objective on the stock in a research note on Wednesday, May 10th. Argus restated a buy rating and issued a $69.00 price objective (up from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, Hilliard Lyons initiated coverage on Zoetis in a research note on Tuesday, June 20th. They issued a buy rating and a $77.00 price objective on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company. Zoetis has an average rating of Buy and a consensus price target of $64.78.

Zoetis (ZTS) traded down 0.07% during mid-day trading on Thursday, reaching $61.35. 744,401 shares of the company’s stock traded hands. The firm has a 50 day moving average of $61.84 and a 200 day moving average of $58.41. The firm has a market cap of $30.01 billion, a PE ratio of 34.68 and a beta of 1.02. Zoetis has a 1-year low of $46.86 and a 1-year high of $63.85.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the previous year, the business posted $0.49 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Analysts forecast that Zoetis will post $2.34 EPS for the current year.

WARNING: “Zoetis Inc. (ZTS) Given a $70.00 Price Target at Cowen and Company” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/25/zoetis-inc-zts-given-a-70-00-price-target-at-cowen-and-company.html.

Several large investors have recently made changes to their positions in the stock. CGOV Asset Management boosted its stake in shares of Zoetis by 2.7% in the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock valued at $12,059,000 after buying an additional 4,405 shares in the last quarter. Huntington National Bank boosted its stake in shares of Zoetis by 15.7% in the first quarter. Huntington National Bank now owns 2,836 shares of the company’s stock valued at $151,000 after buying an additional 385 shares in the last quarter. Retirement Systems of Alabama boosted its stake in shares of Zoetis by 1.6% in the first quarter. Retirement Systems of Alabama now owns 237,808 shares of the company’s stock valued at $12,692,000 after buying an additional 3,745 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Zoetis by 24.4% in the first quarter. Candriam Luxembourg S.C.A. now owns 47,336 shares of the company’s stock valued at $2,526,000 after buying an additional 9,281 shares in the last quarter. Finally, Profund Advisors LLC boosted its stake in shares of Zoetis by 9.2% in the first quarter. Profund Advisors LLC now owns 30,174 shares of the company’s stock valued at $1,610,000 after buying an additional 2,541 shares in the last quarter. Hedge funds and other institutional investors own 92.70% of the company’s stock.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.